LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market
12. April 2022 13:53 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...
Univest Securities, LLC. Announces Closing of IPO for its Client Happiness Biotech Group Limited (NASDAQ: HAPP), Marking the Second Nasdaq IPO of Uinvest in 2019
31. Oktober 2019 09:00 ET
|
Univest Securities, LLC
New York, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Univest Securities, LLC, a FINRA and SIPC member full-service investment bank and securities broker-dealer firm, today announced the closing of previously...
Guardion Health Sciences Announces Pricing of $5.2 Million Underwritten Public Offering
13. August 2019 09:00 ET
|
Guardion Health Sciences, Inc.
San Diego, CA, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), announced the pricing of an underwritten public offering of 13,000,000...
Pure Harvest’s David Lamadrid to Present at WestPark Capital Sales & Equity Conference
15. Mai 2019 09:00 ET
|
Pure Harvest Cannabis Group, Inc.
SANTA MONICA, CA, May 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Pure Harvest Cannabis Group, Inc. (OTC: PCKKD), soon to be trading under ticker (PHCG), a development stage vertically...
Univest Securities, LLC. Announces Closing of IPO for its client Inmune Bio, Inc. (NASDAQ: INMB), marking the first U.S. biotech IPO in 2019
04. Februar 2019 08:57 ET
|
Univest Securities, LLC
New York, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Univest Securities, LLC, a FINRA and SIPIC member full-service investment bank and securities broker-dealer firm, today announced the closing of the...
INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “INMB”
04. Februar 2019 08:55 ET
|
INmune Bio, Inc.
LA JOLLA, CA, Feb. 04, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s innate immune system...